Health X Platform Ltd

- There is no mention of any planned new fundraising through debt or equity in the disclosed transcript. - Banwari Lal Mittal emphasized that the company aims to build the business over the next three years using existing cash reserves without leveraging. - Current cash and near-cash assets stand substantial (around Rs. 675 crores), which management believes is sufficient to support their growth plans. - The expected growth targets (CAGR of 41% leading to Rs. 6,600 crores turnover by 2030) are planned to be achieved without raising additional capital. - The management's focus is on capital efficiency and sustainable profit growth rather than seeking new external capital. - The Japanese marquee investors are supportive and have consented to current investments, but there's no indication of fresh fundraising planned.

- SastaSundar plans to invest around Rs. 145 crores in fresh capital expenditure mainly focused on building the SastaSundar platform and RetailerShakti businesses. - This investment will come from existing capital raised (including Rs. 96 crores from the Flipkart deal) and treasury income. - The Rs. 145 crores will be primarily expenses booked in the Profit & Loss account for technology build-up (self-developed products), salaries for engineers, and marketing/advertisement. - There are no plans for manufacturing; instead, SastaSundar will partner with existing manufacturers. - Expansion plans include opening one new ALC (warehouse) for RetailerShakti in the next 2-3 years (from current three ALCs to a total of four). - Strategic alliances are being explored for expanding the Genu Path Labs (pathology business), integrating it with the quick health platform. - The company aims to remain capital-efficient, avoiding excessive leverage, to grow profitably over the next three years.

- Target total revenue by 2030: Rs. 6,600 crores (combined SastaSundar and RetailerShakti). - SastaSundar platform expected revenue by 2030: Rs. 2,000 crores (60% CAGR from current year). - RetailerShakti expected revenue by 2030: Rs. 4,500 crores (36% CAGR from current year). - Current year (FY '24-'25) projected revenue: Rs. 1,191 crores total (approx. Rs. 200 crores from SastaSundar, Rs. 1,000 crores from RetailerShakti). - RetailerShakti growth: 100% year-over-year from last year, aiming for CAGR of 36% over next five years. - SastaSundar aims to expand SKU portfolio (currently 37,000 SKUs) and launch private label "Aadhaar Pharma" with ~500 SKUs. - EBITDA profitability expected: RetailerShakti by FY '25-'26 and improving to 4%-5% EBITDA margin by 2030. - Plans to double RetailerShakti revenue from Rs. 489 crores (FY '23-'24) to Rs. 1,000 crores (FY '24-'25).

- RetailerShakti is expected to grow at a CAGR of 36% over the next five years, with profitability anticipated around FY 2025-26 when it reaches approximately Rs. 2,000 crores revenue. - SastaSundar platform aims for a 60% growth CAGR, targeting Rs. 2,000 crores in revenue by 2030. - Overall, the combined business aims for Rs. 6,600 crores turnover by 2030, reflecting a blended revenue CAGR of 41% (60% for SastaSundar, 36% for RetailerShakti). - The blended gross margin is targeted to increase to about 11% by 2030, with EBITDA margins for the total business expected between 4%-5% by 2030. - RetailerShakti is expected to achieve positive EBITDA by FY 2025-26 and progressively improve to 1-3% EBITDA margins from FY 2026-27 onwards. - The focused investment of around Rs. 145 crores is expected to be profitable, with PAT profitability at the platform level projected after one year of these investments.

The provided pages of the SastaSundar Ventures Limited Q2 FY '25 Earnings Call transcript do not explicitly mention current or expected order book or pending orders details. Key business updates include: - Revenue projections: FY '24 - '25 expected revenue around Rs. 1,191 crores (SastaSundar ~Rs. 200 crores; RetailerShakti ~Rs. 1,000 crores). - Growth targets for 2030: Composite platform turnover Rs. 6,600 crores (SastaSundar Rs. 2,000 crores; RetailerShakti Rs. 4,500 crores). - SKU portfolio: ~37,000 SKUs currently with plans to expand via new pharma launches, trade generics, and D2C health products. - Capital deployment: Around Rs. 145 crores planned investment to grow both SastaSundar and RetailerShakti businesses. - Focus on volume ramp-up leading to profitability and EBITDA growth. No explicit data on order book or pending orders was disclosed in the sections reviewed.